04:15 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
08:00 , Feb 25, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD5 molecule-like (AIM; CD5L)

Renal disease INDICATION: Renal damage Cell culture and mouse studies suggest AIM could help treat acute kidney injury (AKI). In a mouse model of severe AKI, AIM decreased acute tubular necrosis and accumulation of intratubular...
08:00 , Feb 25, 2016 |  BC Innovations  |  Translation in Brief

AIMing high

Clearing necrotic debris is a critical step in overcoming acute kidney injury (AKI), but failing to turn off the phagocyte response can lead to renal fibrosis in the long term. A Japanese group has shown...
07:00 , Jul 21, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL); hairy cell leukemia CD160; CD23; CD5 Human studies suggest CD160 expression could help diagnose CLL. In mature and immature B cells...
07:00 , Jul 21, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Metabolic disease; diabetes CD5 molecule-like (CD5L; AIM) Studies in mice suggest antagonizing CD5L could help prevent progression from obesity to metabolic syndrome and type 2...
07:00 , Jun 10, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Obesity CD5 molecule-like (CD5L; AIM) In vitro and mouse studies suggest that CD5L could help prevent obesity. In cultured adipocytes, as compared with controls,...
07:00 , Jun 1, 2009 |  BioCentury  |  Regulation

Accelerate, or not

Arzerra ofatumumab from Genmab A/S and partner GlaxoSmithKline plc would appear to be a classic example of why accelerated approval was created. With last Friday's 10-3 vote by the Oncologic Drugs Advisory Committee to recommend...
08:00 , Jan 29, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Fungal infection CD5 In vitro and mouse studies suggest that soluble CD5 could potentially treat fungal sepsis. In protein binding...
07:00 , Oct 30, 2008 |  BC Innovations  |  Distillery Therapeutics

Indication: Transplantation

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Transplantation Graft-versus-host-disease (GvHD) T cell receptor (TCR) Studies in cell culture and in mice suggest that CD4+/CD5+ T regulatory cells (Tregs)...
07:00 , Apr 19, 2004 |  BioCentury  |  Strategy

Making the 'make' decision

Drug discovery and development is like the portion of an iceberg that is above water: visible and dramatic. Manufacturing is like the portion that is under water: out of sight and often out of mind....